EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies

Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death. The accumulation of genetic and epigenetic changes is closely related to the occurrence and development of HCC. Enhancer of zeste homolog 2 (EZH2, a histone methyltransferase) is suggested to be one of the principal factors...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bohan, Liu, Yachong, Liao, Zhibin, Wu, Haofeng, Zhang, Bixiang, Zhang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236851/
https://www.ncbi.nlm.nih.gov/pubmed/37268997
http://dx.doi.org/10.1186/s40164-023-00405-2
_version_ 1785053033641541632
author Wang, Bohan
Liu, Yachong
Liao, Zhibin
Wu, Haofeng
Zhang, Bixiang
Zhang, Lei
author_facet Wang, Bohan
Liu, Yachong
Liao, Zhibin
Wu, Haofeng
Zhang, Bixiang
Zhang, Lei
author_sort Wang, Bohan
collection PubMed
description Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death. The accumulation of genetic and epigenetic changes is closely related to the occurrence and development of HCC. Enhancer of zeste homolog 2 (EZH2, a histone methyltransferase) is suggested to be one of the principal factors that mediates oncogenesis by acting as a driver of epigenetic alternation. Recent studies show that EZH2 is widely involved in proliferation and metastasis of HCC cells. In this review, the functions of EZH2 in HCC progression, the role of EZH2 in tumor immunity and the application of EZH2-related inhibitors in HCC therapy are summarized.
format Online
Article
Text
id pubmed-10236851
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102368512023-06-03 EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies Wang, Bohan Liu, Yachong Liao, Zhibin Wu, Haofeng Zhang, Bixiang Zhang, Lei Exp Hematol Oncol Review Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death. The accumulation of genetic and epigenetic changes is closely related to the occurrence and development of HCC. Enhancer of zeste homolog 2 (EZH2, a histone methyltransferase) is suggested to be one of the principal factors that mediates oncogenesis by acting as a driver of epigenetic alternation. Recent studies show that EZH2 is widely involved in proliferation and metastasis of HCC cells. In this review, the functions of EZH2 in HCC progression, the role of EZH2 in tumor immunity and the application of EZH2-related inhibitors in HCC therapy are summarized. BioMed Central 2023-06-02 /pmc/articles/PMC10236851/ /pubmed/37268997 http://dx.doi.org/10.1186/s40164-023-00405-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Wang, Bohan
Liu, Yachong
Liao, Zhibin
Wu, Haofeng
Zhang, Bixiang
Zhang, Lei
EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
title EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
title_full EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
title_fullStr EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
title_full_unstemmed EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
title_short EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
title_sort ezh2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236851/
https://www.ncbi.nlm.nih.gov/pubmed/37268997
http://dx.doi.org/10.1186/s40164-023-00405-2
work_keys_str_mv AT wangbohan ezh2inhepatocellularcarcinomaprogressionimmunityandpotentialtargetingtherapies
AT liuyachong ezh2inhepatocellularcarcinomaprogressionimmunityandpotentialtargetingtherapies
AT liaozhibin ezh2inhepatocellularcarcinomaprogressionimmunityandpotentialtargetingtherapies
AT wuhaofeng ezh2inhepatocellularcarcinomaprogressionimmunityandpotentialtargetingtherapies
AT zhangbixiang ezh2inhepatocellularcarcinomaprogressionimmunityandpotentialtargetingtherapies
AT zhanglei ezh2inhepatocellularcarcinomaprogressionimmunityandpotentialtargetingtherapies

Ejemplares similares